Skip to main content
AVTX
NASDAQ Life Sciences

Officer Files Intent to Sell $466K in Shares Following Option Exercise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$16.02
Mkt Cap
$296.574M
52W Low
$3.39
52W High
$20.72
52W Position info
373% above low
Off High info
23% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

AVTX has more than doubled off its 52-week low of $3.39.

Summary

An officer of Avalo Therapeutics has filed a Form 144 to sell shares worth approximately $466,558, which were acquired through stock option exercises.


Key Events · Ownership and Investor Activity · AVTX

  • Officer Files Intent to Sell

    Mittie Doyle, an officer of Avalo Therapeutics, Inc., has filed a Form 144 indicating an intent to sell 29,529 shares of common stock.

  • Value of Proposed Sale

    The approximate market value of the shares intended for sale is $466,558.20.

  • Shares Acquired via Option Exercise

    The shares to be sold were acquired through the exercise of stock options.


Analysis · AVTX · Life Sciences

Mittie Doyle, an officer of Avalo Therapeutics, Inc., has filed a Form 144 indicating an intent to sell approximately $466,558 worth of common stock. These shares were acquired through the exercise of stock options. While the sale provides liquidity for the officer, it represents a reduction in insider ownership and could be perceived negatively by investors, signaling a potential lack of confidence or a desire to diversify holdings.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVTX was trading at $16.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $296.6M. The 52-week trading range was $3.39 to $20.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVTX - Latest Insights

AVTX
Nov 05, 2026, 7:58 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.91
Real-time Price: $7.63 info
Change: +$0.720 (+10%) info
Market Cap: $412.279M info
AVTX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.13
Real-time Price: $7.63 info
Change: +$0.500 (+7%) info
Market Cap: $412.279M info
AVTX
Aug 06, 2026, 7:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $7.63 info
Change: -$11.06 (-59%) info
Market Cap: $412.279M info
AVTX
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $7.63 info
Change: -$11.06 (-59%) info
Market Cap: $412.279M info
AVTX
Jun 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.04
Real-time Price: $7.63 info
Change: -$7.41 (-49%) info
Market Cap: $412.279M info